Dr. Kuzel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15300 West Ave
Robert H Lurie Comp Ca Ctr
Orland Park, IL 60462Phone+1 708-226-2513Fax+1 312-942-3192
Summary
- I am the Samuel G Taylor III Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University since June 2016. Prior to that I spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine. I have focused my career on the design and execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics rationally designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents utilized have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. I have been a Co-PI on a SPORE in Prostate Cancer at Northwestern focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies (the grant is in NCE thru Aug 2021). I have also had Prostate Cancer Foundation and NIH funding for translational agent development. I also worked in the area of shared decision making and identification of adverse events associated with drug therapy of cancer. I have served on a number of NCI site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell Ca, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) Community based NCI centers (NCOROP), and Novel Statistical Clinical Programs. In addition, I participated on several NCCN guidelines committees including Kidney/Testis and Bladder and Prostate at various times. I serve on multiple Data Monitoring Committees of phase II and III global check point inhibitor clinical trials.
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
- University of Michigan Medical SchoolClass of 1984
- University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981
- University of MichiganB.S., Biomedical Sciences, 1981
Certifications & Licensure
- IL State Medical License 1984 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
- America's Top Doctors Castle Connolly, 2008-2017
- America's Top Doctors for Cancer Castle Connolly, 2007-2017
- Join now to see all
Clinical Trials
- Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1991 Oct 01
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1999 May 20
- Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1998 May 01
- Join now to see all
Publications & Presentations
PubMed
- 22 citationsIL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic WoundRuchi Roy, Janet Zayas, Mohamed F. Mohamed, Anahita Aboonabi, Kaylee Delgado
The Journal of Investigative Dermatology. 2021-09-10 - 754 citationsPhase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell LymphomaElise A. Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss
Journal of Clinical Oncology. 2007-07-20 - 181 citationsSmall cell carcinoma of the urinary bladderLiang Cheng, Chong-Xian Pan, Ximing J. Yang, Antonio Lopez-Beltran, Gregory T. MacLennan
Cancer. 2004-09-01
Journal Articles
- Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor SuppressionTimothy M Kuzel, Bin Zhang, The Journal of Immunology
- The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to ActionAgne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
- The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature reviewSchwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs LymphomaTimothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of use of Phosphodiesterase Type 5 Inhibitors (PDE5-I) after Radical Prostatectomy (RP) on Biochemical Recurrence-free (BCRF) and Overall Survival (OS): A Retro...Arden B. Roston, Irene B. Helenowski, William Catalona, Robin Leikin, Michael Gurley, Luke Trapp, Borko Jovanovic, Timothy M. Kuzel, J Clin Oncol; Proc of GU ASCO, 1/1/2017
- Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell...Sumanta Pal, Robert J Motzer, Mayer Fishman, Raymond McDermott, Jose Passos Coelho, Evgeniy Kopyltsov, Xavier Garcia del Muro Solans, Jesús Garcia Donas, Ramazan Yildi..., J Clin Oncol; Proc of GU ASCO, 1/1/2017
- Join now to see all
Lectures
- Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...London, United Kingdom - 1/13/2017
- Immunotherapy of Cancer1/1/2012
- A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma.1/1/2009
- Join now to see all
Other
- The use of Gemcitabine in metastatic urothelial transitional cell cancerKuzel TM and Stadler WM, Lilly Monograph
1/1/1996 - Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2.Kuzel TM, Doody's Health Sciences Book Review Annual
1/1/1993 - Interferons: Basic Principles and Clinical Applications.Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
1/1/1993
Press Mentions
- Combination Treatment Improves Survival in Advanced Prostate Cancer with Genetic MutationsSeptember 6th, 2024
- Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
- Personalized Vaccine Helps Patients Fight Ovarian CancerApril 12th, 2018
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: